Recruiting
Phase 3

Heparin vs Placebo

Sponsor:

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Code:

NCT04374799

Conditions

Cardiac Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Heparin

Placebos

Study Details

Brief summary:

Patients undergoing cardiac catheterization will be randomized to 3 groups: no anticoagulant, low dose anticoagulant and high dose anticoagulant.

Conditions

Cardiac Disease

Study ID

NCT04374799

Start date

Oct 5, 2020

Status verified date

Aug, 2025

Completion date

Dec, 2026

Anticipated

Primary completion date

Aug, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • diagnostic cardiac catheterization; Small size sheath; patency of the ulno-palmar circulation

Exclusion Criteria:

abnormal ulno-palmar circulation; Prior radial artery thrombosis; Prior surgery close to the access site; Emergent cardiac catheterization; History of HIT or allergy to heparin; Patients requiring anticoagulation

Study Design

Enrollment

1623 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

active comparator: Low dose heparin

heparin (25 IU/Kg -maximal dose 3,000 IU)

active comparator: High dose heparin

heparin 50 IU/kg -maximal dose 5,000 IU

placebo comparator: Placebo

Normal saline 0.9%.

Interventions

Heparin

two doses of heparin

Placebos

placebo

Primary outcome measure

  • radial artery occlusion [ Time Frame: 1 hour ]

Central Contacts and Locations

Central contacts

Shahar Lavi, MD

519-6633611Shahar.lavi@lhsc.on.ca

Locations

Hamilton Health Sciences

Recruiting

Hamilton, Ontario, Canada

Principal Investigator:

Shamir Mehta, MD

London Health Sciences Centre

Recruiting

London, Ontario, Canada, N6A5A5

Contacts

Shahar Lavi, MD

519-663-3611shahar.lavi@lhsc.on.ca

Cassandra Wagner, MSc

519-685-8500cassandra.wagner@lhsc.on.ca

Principal Investigator:

Shahar Lavi, MD

More Information

Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Last update posted

Feb 20, 2026

Last verified

Aug, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's on 2026-02-20.